Equillium announces up to $50 million financing to advance eq504, a novel aryl hydrocarbon receptor modulator, into the clinic

La jolla, calif.--(business wire)-- #ahrmodulation--equillium, inc. (“equillium” or the “company”) (nasdaq: eq), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced it has entered into a definitive securities purchase agreement with leading healthcare investors that will provide up to $50 million in gross proceeds to equillium. the private placement is comprised of (i) an initial upfront financing of approximately $30 million in gross proce.
EQ Ratings Summary
EQ Quant Ranking